Aggrecan Antibody (Cat-315)
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-29796
Key Product Details
Species Reactivity
Rat, Feline
Applications
Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunoprecipitation, Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgM Clone # Cat-315
Concentration
This product is unpurified. The exact concentration of antibody is not quantifiable.
Product Specifications
Immunogen
Feline brain proteoglycans.
Specificity
Chondroitin sulfate proteoglycan (CSPG), protein core epitope.
Marker
Chondrocyte Marker
Clonality
Monoclonal
Host
Mouse
Isotype
IgM
Scientific Data Images for Aggrecan Antibody (Cat-315)
Immunocytochemistry/ Immunofluorescence: Aggrecan Antibody (Cat-315) [NBP2-29796]
Immunocytochemistry/Immunofluorescence: Aggrecan Antibody (Cat-315) [NBP2-29796] - Mouse anti-CSPG staining of primary cortical culture cells from rat.Applications for Aggrecan Antibody (Cat-315)
Application
Recommended Usage
Immunocytochemistry/ Immunofluorescence
1:500
Immunohistochemistry
1:2000
Immunoprecipitation
1:10-1:500
Western Blot
1:5000
Application Notes
Immunohistochemistry: on 4% paraformaldehyde fixed frozen tissue. Immunocytochemistry/Immunofluorescence :Primary cultures of neurons. ImmunoBlot: recognizes a band at 680 kDa.
Formulation, Preparation, and Storage
Purification
Unpurified
Formulation
Ascites
Preservative
0.1% Sodium Azide
Concentration
This product is unpurified. The exact concentration of antibody is not quantifiable.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
Background: Aggrecan
Additional Aggrecan Products
Product Documents for Aggrecan Antibody (Cat-315)
Product Specific Notices for Aggrecan Antibody (Cat-315)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...